No annual revenue total was found in NUVECTIS PHARMA, INC.'s SEC filings.
Nuvectis Pharma, Inc. (NVCT) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-50.45M
-98.8% vs year-ago TTM
Operating cash flow (TTM)
$-40.29M
-177.9% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-2.03
-49.0% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
26.49M
+13.3% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NVCT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fort Lee, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1875558
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$27.6M | -$19.8M | -$22.9M | -$19.2M |
| Net income | -$26.4M | -$19.0M | -$22.3M | -$19.1M |
| Diluted EPS | -$1.32 | -$1.11 | -$1.43 | -$1.51 |
| Operating cash flow | -$16.0M | -$12.2M | -$16.0M | -$13.6M |
| Total assets | $31.7M | $18.6M | $19.2M | $20.4M |
| Total liabilities | $13.3M | $8.9M | $7.0M | $6.2M |
| Stockholders' equity | $18.4M | $9.7M | $12.2M | $14.2M |
| Cash and investments | $31.6M | $18.5M | $19.1M | $20.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Aug 21, 2026 | Jul 20, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 30, 2026 | Jun 29, 2026 |
All 275 Nuvectis Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.